Literature DB >> 21948969

Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control.

Michelle Hong1, Anne-Laure Puaux, Caleb Huang, Laure Loumagne, Charlene Tow, Charles Mackay, Masashi Kato, Armelle Prévost-Blondel, Marie-Françoise Avril, Alessandra Nardin, Jean-Pierre Abastado.   

Abstract

T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21948969     DOI: 10.1158/0008-5472.CAN-11-1466

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  109 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Immune predictors of cancer progression.

Authors:  Benjamin Toh; Valerie Chew; Xilei Dai; Karen Khoo; Muly Tham; Lu-En Wai; Sandra Hubert; Sumathy Velumani; Liang Zhi; Caleb Huang; Jean-Pierre Abastado
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Authors:  Edmund K Moon; Liang-Chuan S Wang; Kheng Bekdache; Rachel C Lynn; Albert Lo; Stephen H Thorne; Steven M Albelda
Journal:  Oncoimmunology       Date:  2018-01-09       Impact factor: 8.110

4.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

Review 5.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

6.  TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Authors:  Ileana S Mauldin; Ena Wang; Donna H Deacon; Walter C Olson; Yongde Bao; Craig L Slingluff
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

Review 7.  Personalized peptide vaccines and their relation to other therapies in urological cancer.

Authors:  Takahiro Kimura; Shin Egawa; Hirotsugu Uemura
Journal:  Nat Rev Urol       Date:  2017-05-31       Impact factor: 14.432

Review 8.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

Review 9.  Regional therapies for in-transit disease.

Authors:  Paul J Speicher; Claire H Meriwether; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2015-01-30       Impact factor: 3.495

10.  Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Mark E Smolkin; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja V Galeassi; Kimberly A Chianese-Bullock; Lynn T Dengel; Francesco M Marincola; Gina R Petroni; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.